Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company reported a rapid revenue growth in the third quarter of 2025, with a year-on-year increase of 85.26% in revenue and 130.72% in net profit [5][6] - The demand for overseas new products is strong, with a backlog of orders worth approximately 300 million yuan from U.S. customers [6] - The company is expanding its production capacity in Thailand to mitigate high tariff risks and is developing new product lines, which will open new growth opportunities [6][7] Summary by Sections Market Performance - The closing price is 48.35 yuan, with a one-year high/low of 57.00/27.22 yuan [3] Financial Data - For the first three quarters of 2025, the company achieved a revenue of 448 million yuan (up 40.47% year-on-year) and a net profit of 136 million yuan (up 40.03% year-on-year) [5] - The gross margin for the first three quarters is 66.55%, an increase of 0.81 percentage points year-on-year [6] Revenue and Profit Forecast - Revenue projections for 2025-2027 are 586 million, 738 million, and 903 million yuan, with year-on-year growth rates of 32.32%, 25.99%, and 22.35% respectively [7] - Net profit forecasts for the same period are 185 million, 237 million, and 295 million yuan, with growth rates of 36.34%, 28.62%, and 24.27% respectively [7] Valuation Metrics - The current price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are projected to be 31x, 24x, and 20x respectively [7]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [5] Core Views - The company achieved a revenue growth of 30% year-on-year for Q1-Q3 2025, actively expanding into tea beverage ingredients and konjac food applications [5][7] - The konjac powder business showed a significant increase in both volume and price, contributing to the overall revenue growth [7] - The company is focusing on high-value markets, including health-oriented and functional food segments, leveraging its technological advancements and strong supply chain [7] Financial Performance Summary - For 2025, the company is projected to generate revenue of 777 million yuan, with a year-on-year growth rate of 26.01% [6] - The net profit attributable to shareholders is expected to be 91 million yuan in 2025, reflecting a growth rate of 4.76% [6] - The earnings per share (EPS) is forecasted to be 0.88 yuan in 2025, with a price-to-earnings (P/E) ratio of 43.59 [6][8] Business Development Insights - The company has expanded its tea beverage ingredient production capacity to approximately 60,000 tons, with plans to increase it to 80,000 tons based on market feedback [7] - The konjac food business has seen a revenue increase of 57.96% year-on-year in the first half of 2025, driven by strong sales of konjac crystal products [7] - The company is also promoting 15,000 tons of konjac ingredients in the domestic market, targeting various food service channels [7]

Report Investment Rating - The report is bullish on the bond market, predicting that the yield of the 10Y Treasury bond will return to around 1.65%, the 30Y Treasury bond to 1.9%, and the 5Y large - bank secondary capital bond to 1.9% (all referring to non - VAT bonds) by the end of the year [24]. Core Viewpoints - In October 2025, the wealth management scale increased more than seasonally, with the total scale reaching 33.6 trillion yuan at the end of October, up 3.7 trillion yuan from the end of the previous year and 1.5 trillion yuan from the end of the previous month [3][6]. - The average monthly annualized yield of pure fixed - income wealth management products of wealth management companies significantly rebounded in October. The average performance comparison benchmark of newly issued RMB fixed - income wealth management products of wealth management companies has been declining since the beginning of 2022, and the lower limit may reach 2.0% in the future [3]. - The interest - bearing liability cost rate of A - share listed banks has declined rapidly in the past two years. It is expected to fall below 1.60% in Q4 2025, and the liability cost of commercial banks will decline year by year in the next three to five years, supporting the downward trend of bond yields [3]. - The report is bullish on the bond market in the short term. Factors such as high equity positions of institutions like annuities, rapid decline in bank liability costs, loose liquidity, and seasonal patterns are expected to support the bond market [3]. Summary by Directory 10 - month Wealth Management Scale - As of the end of October 2025, the wealth management scale reached 33.6 trillion yuan, hitting a historical high. The increase in October was 1.5 trillion yuan, higher than the average increase of 0.87 trillion yuan from 2021 - 2024. Even with a strong stock market in Q3 2025, the wealth management scale increased by 1.46 trillion yuan, higher than the same period from 2022 - 2024 [6][7][9]. Fixed - income Wealth Management Yield in October 2025 - The performance comparison benchmark of newly issued RMB fixed - income wealth management products has been declining since 2022. In October 2025, the upper limit was 2.61% and the lower limit was 2.13%, and the lower limit may drop to around 2.0% in the future [12][17]. - The average 7 - day annualized yield of cash - management wealth management products was 1.26% as of November 9, 2025, and that of money market funds was 1.11%. The yield of cash - management products was stable at a low level in October [13][15]. - The fixed - income wealth management yield significantly rebounded in October. The average monthly annualized yield of pure fixed - income wealth management products was 3.53% in October, up from 2.15% in September [18]. Investment Advice - The interest - bearing liability cost rate of A - share listed banks decreased to 1.63% in Q3 2025, and it is expected to fall below 1.60% in Q4 2025. In the next three to five years, the liability cost of commercial banks will decline year by year, supporting the downward trend of bond yields [19]. - Given high equity positions of institutions like annuities, rapid decline in bank liability costs, loose liquidity, and expected policy rate cuts, the report is bullish on the bond market. Wealth management products may increase their allocation of credit bonds with a remaining maturity of 3 years or less and long - term industrial and urban investment bonds [24].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's profit is under short-term pressure, but overseas reagent growth is driving an optimization of the profit structure [5] - In the first three quarters of 2025, the company achieved operating revenue of 3.428 billion yuan (yoy +0.39%) and a net profit attributable to the parent company of 1.205 billion yuan (yoy -12.92%) [5] - The third quarter of 2025 saw operating revenue of 1.243 billion yuan (yoy +3.28%) and a net profit of 434 million yuan (yoy -9.72%) [5] Summary by Sections Market Performance - The closing price is 62.34 yuan, with a one-year high of 72.90 yuan and a low of 49.01 yuan [3] Financial Performance - The company reported a gross margin of 68.73% (yoy -3.61pct) in the first three quarters of 2025, with a sales expense ratio of 16.86% (yoy +1.56pct) and a management expense ratio of 2.65% (yoy +0.06pct) [7] - The company’s revenue is projected to be 4.858 billion yuan in 2025, with a growth rate of 7.12% [8] - The net profit attributable to the parent company is expected to be 1.832 billion yuan in 2025, with a growth rate of 0.17% [8] Regional Performance - Domestic market revenue for the first three quarters was 1.955 billion yuan (yoy -11%), while overseas market revenue was 1.467 billion yuan (yoy +21%) [6] - The overseas reagent revenue grew by 37%, leading to an increase in the overall gross margin to 69.49% [6] Product Development - The company has installed 1,144 units of fully automated chemiluminescence analyzers, with 78% being large machines [6] - Revenue from small molecule detection reagents increased by 74% year-on-year, indicating a rapid rise in market acceptance [7] Earnings Forecast - The company expects revenues of 4.858 billion yuan in 2025, 5.496 billion yuan in 2026, and 6.348 billion yuan in 2027, with corresponding net profits of 1.832 billion yuan, 2.065 billion yuan, and 2.385 billion yuan [8]

Investment Rating - The report highlights a focus on the power equipment industry chain in the context of the rapid growth in electricity demand driven by artificial intelligence technology [1]. Core Insights - The global electricity demand for data centers is projected to reach 945 TWh by 2030, with a current consumption of 415 TWh in 2024, representing 1.5% of global electricity consumption, and growing at an annual rate of 12% [3][9]. - The report identifies 16 companies within the North Exchange's power equipment industry chain, including key players such as Kai Fa Technology, Guangxin Technology, and Can Energy [3][45]. - The median price-to-earnings (P/E) ratio for the electronic equipment industry on the North Exchange has increased from 60.1X to 60.5X, indicating a slight upward trend in valuation [51]. Summary by Sections 1. Current AI Technology Development Driving Electricity Demand Surge - AI operations currently face a lack of sufficient electricity, with projections indicating that global data center electricity demand could reach 945 TWh by 2030 [7][18]. - The rapid increase in electricity demand is pushing the global energy system towards a critical turning point [9]. 2. Total: Median Price Change of North Exchange Technology Growth Stocks at -3.57% - As of November 7, 2025, the median price change for technology growth stocks on the North Exchange was -3.57%, with 27 companies experiencing an increase [47][50]. - Notable gainers included Can Energy (+31.13%) and Hongxi Technology (+19.07%) [49]. 3. Industry: Electronic Equipment Industry P/E Ratio Median Increased by 0.70% to 60.5X - The median P/E ratio for the electronic equipment industry rose to 60.5X, with the total market value decreasing from 1509.9 billion to 1461.4 billion [51][52]. - The report notes a decrease in the number of companies in the >100X P/E ratio category, while those in the 30X-50X and 50X-100X categories increased [51][54]. 4. Announcements - Tianhong Lithium Battery is establishing a joint venture to further develop its energy storage independent power station business [4][38]. - Kai Fa Technology plans to invest in new projects with a total investment of 283.7 million yuan [4][38].

Fixed Income - October foreign trade underperformed expectations, while prices showed some recovery, indicating potential economic downward pressure in Q4 [7] - The cumulative year-on-year growth of fixed asset investment showed negative growth, suggesting that traditional investment-driven economic models may no longer be sustainable [7] - The consumer sentiment remains low, with October's price recovery being weak, reflecting a lack of domestic economic recovery momentum [7] - The cancellation of tariffs on fentanyl by the US and the extension of the suspension of reciprocal tariffs may provide some support for foreign trade in November and December [7] - The bond market remains optimistic, with the expectation of further policy interest rate cuts as the cost of interest-bearing liabilities for banks declines [7] Credit Analysis - The credit spread for most industries has compressed, with significant reductions in city investment bonds [11] - The credit market is expected to maintain a relatively optimistic outlook in November due to several factors, including high historical percentiles for mid-to-long-term credit bonds and a favorable funding environment [14] - The overall credit market saw a decrease in transaction volume, but the credit spreads for various industries showed different degrees of compression [12][14] New Consumption - The beauty market in China showed steady performance, with retail sales of cosmetics growing by 3.9% year-on-year from January to September 2025, outperforming the overall retail sales growth [16] - The personal care segment performed better than the overall beauty market, with significant growth in specific brands driven by product innovation and channel expansion [17] - Domestic leading brands are expected to continue their strong performance due to their multi-faceted advantages in branding, products, channels, and management [18] Food Container Industry - The food container industry is experiencing steady expansion, driven by diverse downstream demand [20] - The global food container market is projected to grow from $163.7 billion in 2024 to $227.3 billion by 2032, with a compound annual growth rate of 4.19% [21] - The proposed listing of New Tianli, a leading company in the thermoformed food container industry, is expected to enhance its influence in the market [20][21] Agriculture - The pig breeding industry is undergoing significant policy transformations, with a notable decline in breeding stock and an increase in the culling of sows [25][26] - The price of pork has dropped below the industry cost line, leading to accelerated capacity reduction in the industry [26] - The poultry industry faces a "high capacity, weak consumption" contradiction, with leading companies expected to gain market share [28] - Recommendations include focusing on cost-efficient leading companies in the agriculture sector, which are likely to benefit from policy support and market dynamics [27]

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company achieved a revenue growth of 31% year-on-year for Q1-Q3 2025, driven by new product launches and the multi-faceted empowerment from Yangshengtang [4][5] - The forecasted net profits for the company from 2025 to 2027 are expected to be 879 million, 1.217 billion, and 1.56 billion RMB respectively, with corresponding P/E ratios of 31, 22, and 17 times based on the closing price on November 7, 2025 [5] Financial Performance Summary - For Q1-Q3 2025, the company reported a revenue of 1.296 billion RMB (yoy +31%) and a net profit of 568 million RMB (yoy +9%) [7] - The revenue growth is primarily attributed to the increase in sales of medical devices and functional skincare products, with a notable rise in the sales of A-type recombinant human collagen products [7] - The company’s revenue for 2025 is projected to reach 1.904 billion RMB, with a year-on-year growth rate of 31.98% [6][8] - The gross profit margin is expected to remain high at around 90% for the coming years, indicating strong profitability [8] Product and Market Development - The company launched the new HiveCOL collagen product in July 2025, which is anticipated to drive growth in the medical aesthetics sector [7] - The company is actively expanding its market presence through online promotions and collaborations with both international and domestic brands, enhancing its sales channels [7] - The company has received regulatory approval for its recombinant type III human collagen freeze-dried fibers, which have broad application prospects in various medical fields [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is experiencing an increase in shipment volume, but profitability is under pressure due to market competition and supply chain costs [6] - The company has shown strong performance in the third quarter, with a significant increase in smartphone shipments, achieving a year-on-year growth of 13.6% [6] - The company is actively adapting to cost pressures and is expected to restore profitability through price adjustments and product structure optimization [6] - The company is positioned to benefit from the upcoming commercialization of edge AI technology, enhancing its hardware value proposition [6] Financial Summary - Revenue projections for the company are as follows: - 2023: 62,295 million RMB - 2024: 68,715 million RMB - 2025E: 69,922 million RMB - 2026E: 80,637 million RMB - 2027E: 90,387 million RMB - Year-on-year growth rates for revenue are projected at 33.69% for 2023, 10.31% for 2024, and 1.76% for 2025E [5][6] - The company's net profit attributable to shareholders is forecasted as follows: - 2023: 5,537 million RMB - 2024: 5,549 million RMB - 2025E: 3,039 million RMB - 2026E: 4,073 million RMB - 2027E: 5,898 million RMB [5][6] - The company's earnings per share (EPS) for the forecasted years are: - 2023: 4.81 RMB - 2024: 4.82 RMB - 2025E: 2.64 RMB - 2026E: 3.54 RMB - 2027E: 5.12 RMB [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) due to innovation-driven transformation and growth opportunities in AI and automotive sectors [5]. Core Views - The company is experiencing a transformation driven by innovative business segments, particularly in AI and automotive applications, which are expected to open up new growth avenues [5]. - The company reported a decline in revenue and net profit for the first three quarters of 2025, but showed strong growth in innovative display products and significant improvements in cash flow [6]. - The company is actively expanding its automotive display business and has established partnerships with major suppliers, indicating a strategic shift towards diversification [6]. Financial Summary - Revenue projections for 2025 are estimated at 16,146 million RMB, with a year-on-year growth rate of 3.59% [5]. - The net profit for 2025 is projected to be 737 million RMB, reflecting a decline of 11.55% compared to the previous year [5]. - The earnings per share (EPS) for 2025 is expected to be 1.05 RMB, with a price-to-earnings (P/E) ratio of 21.38 [5]. - The company’s total market capitalization is approximately 15,757.23 million RMB, with a circulating market value of 11,120.25 million RMB [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The report emphasizes the value of the ATTC platform and the continuous development of potential pipelines [5][7] - The company is advancing innovative treatments for cancer and immune diseases, showcasing its proprietary ATTC platform and the latest progress in late-stage pipeline candidates [7] Financial Performance and Forecast - The company’s projected revenues for 2025, 2026, and 2027 are $567 million, $676 million, and $816 million respectively, with growth rates of -10.0%, 19.2%, and 20.7% [6][8] - The expected net profit for 2025, 2026, and 2027 is $426 million, $94 million, and $138 million respectively, with growth rates of 1029.3%, -78.0%, and 46.7% [6][8] - The report anticipates a reasonable equity value of HKD 26.9 billion based on DCF calculations, assuming a perpetual growth rate of 2% and a WACC of 9.43% [7] Pipeline Development - The ATTC platform is a novel cancer precision therapy development platform that combines monoclonal antibodies with proprietary targeted small molecule inhibitors, aiming for superior anti-tumor activity and safety [7] - The first potential pipeline candidate from this platform is HMPL-A251, which has shown promising anti-tumor efficacy and tolerability in preclinical studies, with plans to enter clinical development by the end of 2025 [7] - Ongoing projects include: 1. FRUSICA-2 study for fruquintinib combined with sintilimab in renal cell carcinoma [7] 2. SANOVO study for savolitinib in non-small cell lung cancer [7] 3. Ongoing studies for surufatinib in pancreatic cancer [7] 4. HMPL-453 for intrahepatic cholangiocarcinoma, with plans for a new drug application in mid-2026 [7]